Evidence map›Paper›PMID 33608311›Full record

ReviewCancer genomics & proteomics

Androgen Receptor and

Aliki Ntzifa, Areti Strati, Georgia-Angeliki Koliou, Flora Zagouri, Dimitrios Pectasides, George Pentheroudakis, Christos Christodoulou, Helen Gogas, Christina Magkou, Constantina Petraki and 5 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Aliki NtzifaAnalysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Areti StratiAnalysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Georgia-Angeliki KoliouSection of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Dimitrios PectasidesOncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
George PentheroudakisDepartment of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
Christos ChristodoulouSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Helen GogasFirst Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Christina MagkouPathology Department, Evangelismos Hospital, Athens, Greece.
Constantina PetrakiDepartment of Pathology, Metropolitan Hospital, Piraeus, Greece.
Paris KosmidisSecond Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Gerasimos AravantinosSecond Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Vassiliki KotoulaDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Evi LianidouAnalysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece; lianidou@chem.uoa.gr.
National and Kapodistrian University of Athens · GRMetropolitan Hospital · GRAristotle University of Thessaloniki · GREvangelismos Hospital · GRHellenic Cooperative Oncology Group · GRHippocration General Hospital · GRHospital Agioi Anargyroi · GRHygeia Hospital · GRLimassol General Hospital · CYUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimEffective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpression is also implicated. PIM1 kinases phosphorylate AR, thus regulating its transcriptional activity, regardless of the presence or not of androgens. We evaluated the expression of AR and PIM1 and their prognostic significance in TNBC. MATERIALS AND

methodsAR and PIM1 transcripts were quantified by quantitative reverse transcription polymerase chain reaction in formalin-fixed paraffin-embedded tumor from 141 patients with TNBC.

resultsAR was expressed in 38.3%, PIM1 in 10.6%, while co-expression of AR and PIM1 was detected in 7/141 cases (5.0%). No prognostic significance of AR or PIM1 was reached for overall or disease-free survival.

conclusionCo-expression of AR and PIM1 exists in only in a small percentage of patients with TNBC. The implications of this finding in the therapeutic management of patients with TNBC should be investigated in larger patient cohorts.

Indexed as

AdultAgedAged, 80 and overAnimalsFemaleHumansMiceMiddle AgedProto-Oncogene Proteins c-pim-1Receptors, AndrogenTriple Negative Breast NeoplasmsYoung AdultPIM1 protein, humanProto-Oncogene Proteins c-pim-1Receptors, Androgenandrogen receptorPIM1RT-qPCRTriple-negative breast cancer

Identifiers

PMID33608311
PMCPMC7943211
OpenAlexW3130025017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.